Crizotinib Current Events | Page 2

Crizotinib Current Events, Crizotinib News Articles.
Sort By: Most Viewed | Most Recent
Page 2 of 3 | 120 Results
Targeted therapy boosts lung cancer outcomes
Non-small cell lung cancer patients whose tumor cells had an abnormal ALK gene fared better if treated with crizotinib, a targeted therapy, than with traditional chemotherapy. Median progression-free survival was 7.7 months in the crizotinib group and three months in the chemotherapy group. Patients treated with crizotinib also reported a better quality of life than those treated with standard chemotherapy. (2013-06-01)

Bronchial carcinoma: Added benefit of crizotinib for first-line treatment not proven
In the only study of direct comparison, carboplatin in the control arm was not used in compliance with the Pharmaceutical Directive. (2016-04-08)

Phase 3 eXalt3 study shows significantly longer progression-free survival
Patients with non-small cell lung cancer (NSCLC) carrying anaplastic lymphoma kinase (ALK) gene alterations who received ensartinib experienced substantially longer progression-free survival than a matched group of patients who received crizotinib. (2020-08-08)

RET rearrangement a new oncogene and potential target in lung cancer
In results presented at ASCO 2013, a University of Colorado Cancer Center study provides important details for a recently identified driver and target in lung adenocarcinoma: Rearrangement of the gene RET. (2013-06-02)

Study defines criteria for MET-driven lung cancer suitable for crizotinib treatment
CU Cancer Center study presented at 16th World Conference on Lung Cancer defines criteria for MET-amplified cancer likely sensitive to treatment with crizotinib. (2015-09-08)

Patient-reported outcomes from the randomized phase III CROWN study of first-line Lorlatinib versus in ALK+ NSCLC
Patient-reported outcomes from the phase III CROWN study showed that time to treatment deterioration (TTD) in pain in chest, dyspnea, and cough was comparable between those who received lorlatinib and patients who took crizotinib. The research was presented today at the International Association for the Study of Lung Cancer's 2020 World Conference on Lung Cancer Singapore. (2021-01-31)

Whose numbers determine cost-effectiveness of targeted anti-cancer therapies?
'Increasingly physicians are being presented with health economic analyses in mainstream medical journals as a means of potentially influencing their prescribing. However, it is only when you understand the multiple assumptions behind these calculations that you can see that they are by no means absolute truths,' says D. Ross Camidge, M.D., Ph.D., investigator at the University of Colorado Cancer Center. (2015-02-02)

Ceritinib in advanced lung cancer: No hint of added benefit
The drug manufacturer's dossier contained no study data suitable for an assessment for any of the two research questions. (2015-10-06)

Significant discrepancies between FISH and IHC results for ALK testing
The findings of a recent study indicate that routine testing with both fluorescent in situ hybridization and immunohistochemistry may enhance the detection of ALK-positive non-small cell lung cancer. (2014-02-24)

ASCO 2019: 40-50 percent response rate for brigatinib after other next-gen ALK inhibitors
University of Colorado Cancer Center study presented at ASCO 2019 shows that brigatinib remains effective even after treatment with another next-generation ALK inhibitor (2019-05-30)

In a childhood cancer, basic biology offers clues to better treatments
By studying tumor biology at the molecular level, researchers are gaining a deeper understanding of drug resistance -- and how to avoid it by designing pediatric cancer treatments tailored to specific mutations in a child's DNA. Their target is neuroblastoma, an often-deadly cancer of the peripheral nervous system. (2011-11-09)

Advance in lung cancer treatment
Scientists from the University of Colorado Cancer Center have once again advanced the treatment of a specific kind of lung cancer. The team has documented how anaplastic lymphoma kinase positive advanced non-small cell lung cancer becomes resistant to a drug targeting the abnormal protein in the cancer. It's the first time scientists have analyzed the frequency and type of drug resistance in ALK positive patients taking crizotinib. (2012-01-18)

Benefit of targeted lung cancer therapy confirmed
A drug that targets a specific type of lung cancer shows a dramatic response in more than half of the people who take it. The drug, called crizotinib, has been in clinical trials since 2006, and the results from the largest group of patients to take it within the first of these clinical trials are being presented at the annual meeting of the American Society of Clinical Oncology. (2011-06-03)

Clinical insight improves treatment with new lung cancer drug
Men experience a marked drop in their testosterone levels when taking a targeted therapy to control a specific type of lung cancer. (2012-04-04)

FDA continues recent trend of approval with new 2nd generation lung cancer treatment
The International Association for the Study of Lung Cancer is once again gratified to see the approval of a new second-generation lung cancer treatment that can help many patients with the FDA's rapid progression of lung cancer drug approvals -- this time for alectinib for patients with advanced (metastatic) ALK-positive non-small cell lung cancer if their disease deteriorated after treatment with another therapy called crizotinib. Patients who could not tolerate treatment with crizotinib also qualify for use of alectinib. (2015-12-23)

Massachusetts General study defines a new genetic subtype of lung cancer
Investigators at the Massachusetts General Hospital Cancer Center have defined the role of a recently identified gene abnormality - rearrangements in the ROS1 gene - in a deadly form of lung cancer. ROS1-rearranged tumors represent one to two percent of non-small-cell lung cancers, the leading cause of cancer death in the US. The researchers also show that ROS1-driven tumors can be treated with crizotinib and describe the remarkable response of one patient to crizotinib treatment. (2012-01-31)

New targeted lung cancer drug produces 'dramatic' symptom improvement
A clinical trial of a new targeted drug has provided powerful evidence that it can halt or reverse the growth of lung tumors characterized by a specific genetic abnormality. The multi-institutional research team reports that daily doses of crizotinib shrank the tumors of more than half of a group patients whose tumors were driven by alterations in the anaplastic lymphoma kinase gene and suppressed tumor growth in another one-third of study participants. (2010-10-27)

Serial analysis of CTCs may provide biomarker predictive of NSCLC response to crizotinib
Among patients with non-small cell lung cancer (NSCLC) fueled by ALK gene alterations who were being treated with crizotinib (Xalkori), a decrease in the number of circulating tumor cells (CTCs) harboring increased copies of the ALK gene over the first two months of treatment was associated with increased progression-free survival. (2017-05-01)

New weapons in the fight against cancer
Several new first-in-man studies for drugs targeted against a range of cancers were released at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna. (2012-09-30)

Alectinib: ALEX and ALUR trials show CNS benefit in NSCLC
Data from two separate phase 3 studies to be presented at the ESMO 2017 Congress in Madrid, show alectinib's particular central nervous system (CNS) activity in patients with advanced non-small cell lung cancer involving a mutation of the anaplastic lymphoma kinase gene (ALK-positive NSCLC). (2017-09-05)

Big data study identifies new potential target coating for drug-eluting stents
A new study has identified an FDA approved cancer drug, crizotinib, as a possible new coating for drug-eluting stents. Researchers found that crizotinib in mice helped prevent the narrowing of blood vessels after stenting without affecting the blood vessel lining. Results of this study were published today in the Journal of Clinical Investigation. (2014-11-18)

People with specific kind of lung cancer respond to new targeted treatment
A study in the New England Journal of Medicine shows more than half of patients with a specific kind of lung cancer are responding positively to a treatment that targets the gene that drives their cancer. (2010-10-28)

Study: Redefining the criteria for ALK positive lung cancer
A University of Colorado Cancer Center study published today in the journal Cancer shows that the current criteria used to match lung cancers with the drug crizotinib may miss some patients who could benefit from the drug. (2013-09-10)

Validation of an IHC screening tool for ROS1 gene rearrangements
Immunohistochemistry (IHC) is an effective tool that can be used for identifying proto-oncogene 1 receptor tyrosine kinase (ROS1) gene rearrangements and screening patients for the administration of the targeted therapy crizotinib, a small-molecule tyrosine kinase inhibitor. (2016-05-11)

Clinical observation leads to lung cancer discovery
A discovery at University of Colorado Cancer Center shows testing lung cancer on a molecular level can produce new insights into this deadly disease. (2011-03-07)

Children with cancer have complete responses in a Children's Oncology Group phase 1 trial
A pill designed to zero in on abnormal genes that drive specific cancers has produced encouraging early results in children with an uncommon but aggressive type of lymphoma, as well as in children with a rare form of neuroblastoma. A phase 1 clinical trial of the drug crizotinib achieved remissions, with minimal side effects, for 10 of the children participating in a clinical study carried out by the multicenter Children's Oncology Group. (2012-05-16)

Classification of gene mutations in a children's cancer may point to improved treatments
Oncology researchers studying gene mutations in the children's cancer neuroblastoma are refining their diagnostic tools to predict which patients are more likely to respond to drugs called ALK inhibitors that target such mutations. (2014-11-10)

New approach to genetic testing leads to dramatic response in MET fusion lung cancer
University of Colorado Cancer Center case study published today in the journal JCO Precision Oncology tests for alterations in many genes simultaneously, resulting in the first published report describing successful targeting of MET fusion in a lung cancer patient. (2017-08-30)

CTCA doctor presents studies at World Conference on Lung Cancer in Australia
Glen J. Weiss, M.D., Director of Clinical Research, Cancer Treatment Centers of America® is presenting two key studies, including one today at the International Association for the Study of Lung Cancer's 15th World Conference on Lung Cancer being held in Sydney, Australia. (2013-10-31)

Scientists develop new strategy to overcome drug-resistant childhood cancer
A new drug combination could offer hope to children with neuroblastoma - one of the deadliest forms of childhood cancer - by boosting the effectiveness of a promising new gene-targeted treatment. Researchers at the Institute of Cancer Research in London have found a way to overcome the resistance of cancer cells to a drug called crizotinib, which recently showed positive early results in its first trial in children with cancer. (2012-07-11)

New research confirms need for lung cancer testing
Different kinds of lung cancer behave in different ways, suggesting they are fundamentally different diseases. According to a University of Colorado Cancer Center study published in Cancer, the official journal of the American Cancer Society, different subgroups of non-small cell lung cancer show distinct patterns of spread in the body. (2012-02-02)

Study: Inexpensive method detects ALK rearrangement in lung cancer patients
A relatively simple and inexpensive method may be used to determine whether a lung cancer patient is a candidate for crizotinib therapy, according to research published in the August issue of the Journal of Thoracic Oncology, the official monthly journal of the International Association for the Study of Lung Cancer. (2011-08-02)

ALK rearrangement found in nearly 10 percent of patients in Lung Cancer Mutation Consortium
ALK rearrangement has been found in 9.6 percent of lung cancer patients tested in the Lung Cancer Mutation Consortium, and MET amplification in another 4.1 percent, reflecting how many patients might benefit from targeted therapies such as crizotinib, according to research presented at the 14th World Conference on Lung Cancer in Amsterdam, hosted by the International Association for the Study of Lung Cancer. (2011-07-05)

Alectinib provides longer symptom improvement than crizotinib in ALK-positive lung cancer
The findings of the ALEX trial presented at the ELCC (European Lung Cancer Congress) 2018 in Geneva, Switzerland, support the use of alectinib as the new standard of care in the frontline treatment of ALK-positive lung cancer. Alectinib was found to provide longer symptom improvement than crizotinib in ALK-positive non-small-cell lung cancer. (2018-04-12)

TGen study identifies gene fusion as likely cause of rare type of thyroid cancer
In a scientific first, the fusion of two genes, ALK and EML4, has been identified as the genetic driver in an aggressive type of thyroid cancer, according to a study by the Translational Genomics Research Institute. These groundbreaking findings are based on genetic sequencing of tumor cells from a 62-year-old patient with an aggressive tall cell variant of papillary thyroid cancer, according to the study published Tuesday, March 18, in the World Journal of Surgery. (2014-03-19)

TGen-Virginia G. Piper Cancer Center launches clinical trial for drug to treat lung cancer
Patients at Virginia G. Piper Cancer Center Clinical Trials are the first in the nation to participate in a clinical trial to determine the safety, tolerability and preliminary activity of an investigational drug that targets cell-signaling proteins associated with the most common form of lung cancer, as well as other forms of cancer such as lymphomas and neuroblastoma. (2011-09-21)

Of mice and men
A known drug, imatinib, can be used to treat a highly aggressive type of lymphoma. The animal model study also demonstrating a striking success in a human patient was largely undertaken in the group of Lukas Kenner at the Ludwig Boltzmann Institute for Cancer Research and the Medical University of Vienna with the support of Karoline Kollmann and Veronika Sexl at the Vetmeduni Vienna and others. The findings are published in (2012-10-15)

New tool uses 'drug spillover' to match cancer patients with treatments
An article in the journal Bioinformatics from researchers at the University of Colorado Cancer Center describes a new tool that improves the ability to match drugs to disease: the Kinase Addiction Ranker predicts what genetics are truly driving the cancer in any population of cells and chooses the best 'kinase inhibitor' to silence these dangerous genetic causes of disease. (2015-07-28)

Adding crizotinib to radiation therapy may help preserve hearing in patients with NF2
A Massachusetts General Hospital research team reports that the use of crizotinib to block a specific molecular pathway both enhanced the radiosensitivity of tumors in mouse models of NF2, allowing a reduction in radiation dosage, and inhibited the growth of cultured tumor cells from NF2 patients. (2018-02-05)

Pairing targeted drugs for breast and lung cancer could overcome treatment resistance
Targeted drugs for breast and lung cancer could be used together to overcome resistance to treatment in several different tumour types, a new study shows. Scientists discovered that when the breast cancer drug palbociclib was combined with the lung cancer drug crizotinib, the two-drug combination was significantly more effective against cancer cells in the laboratory than either drug used on its own. (2019-07-11)

Page 2 of 3 | 120 Results
   First   Previous   Next      Last   
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.